Skip to Content

Pfizer, US ink $5.29B deal for possible COVID-19 treatment

Akhmad Fauzi / CC BY 3.0

By TOM MURPHY
AP Health Writer

The U.S. government will pay drugmaker Pfizer $5.29 billion for 10 million treatment courses of its potential COVID-19 treatment if regulators authorize it. Pfizer asked U.S. regulators on Tuesday to authorize emergency use of its experimental pill, which has been shown to significantly cut the rate of hospitalizations and deaths among people with COVID-19. Pfizer reported earlier this month that its pill cut hospitalizations and deaths by 89% among high-risk adults who had early symptoms. The Food and Drug Administration is already reviewing a competing pill from Merck and will hold a public meeting on it later this month.

Article Topic Follows: Coronavirus Coverage

Jump to comments ↓

Author Profile Photo

Associated Press

BE PART OF THE CONVERSATION

KIFI Local News 8 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content